Trial intelligence / Profile preview

First-line rituximab exploratory study in new-onset lupus nephritis

2017-001619-35Phase 4Terminated

Sponsor: Cliniques universitaires Saint-Luc
Start: Apr 2017
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 4, open-label, single-arm trial of rituximab in lupus nephritis (LN), sponsored by Cliniques universitaires Saint-Luc. Primary endpoint: Disappearance of intra-renal and urinary plasmablasts. Started Apr 2017; status: terminated.

Drugs

rituximab

Conditions

lupus nephritis (LN)

Beyond the preview

Go deeper on 2017-001619-35.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2017-001619-35.